Barclays analyst Lauren Lieberman lowered the firm’s price target on Keurig Dr Pepper to $37 from $42 and keeps an Overweight rating on the shares. The company reiterated its top and bottom line guidance for 2023, but the coffee miss in Q1 and softened outlook drove a stock selloff, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KDP:
- Keurig Dr Pepper backs FY23 adjusted EPS growth 6%-7%, consensus $1.79
- Keurig Dr Pepper reports Q1 adjusted EPS 34c, consensus 33c
- Keurig Dr Pepper to clear consensus in Q1, says RBC Capital
- KDP Upcoming Earnings Report: What to Expect?
- Keurig Dr Pepper call volume above normal and directionally bullish
